aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАНateroskleroz-677Research ArticleОБЗОРЫREVIEWSНекоторые новые перспективные подходы к коррекции липидного фактора риска атеросклерозаSome new perspectives for the correction of lipid risk factor of atherosclerosisНикитинЮ. П.NikitinYu. P.

Юрий Петрович Никитин, д-р мед. наук, проф., академик, зав. лабораторией

СО РАМН

ФГБУ «НИИ терапии и профилактической медицины»

лаборатория этиопатогенеза и клиники внутренних заболеваний

630089

ул. Бориса Богаткова, 175/1

Новосибирск

SB RAMS

Federal State Budgetary Institution "Research Institute of Therapy and Preventive Medicine"

630089

st. Boris Bogatkov, 175/1

Novosibirsk

yuri-nikitin@ngs.ruСимоноваГ. И.SimonovaG. I.

Галина Ильинична Симонова, д-р мед. наук, проф., зав. лабораторией

СО РАМН

ФГБУ «НИИ терапии и профилактической медицины»

лаборатория клинико-популяционных и профилактических исследований терапевтических и эндокринных заболеваний

630089

ул. Бориса Богаткова, 175/1

Новосибирск

SB RAMS

Federal State Budgetary Institution "Research Institute of Therapy and Preventive Medicine"

630089

st. Boris Bogatkov, 175/1

Novosibirsk

МакаренковаК. В.MakarenkovaK. V.

Ксения Владимировна Макаренкова, аспирант, младший научный сотрудник, кардиолог

СО РАМН

ФГБУ «НИИ терапии и профилактической медицины»

лаборатория этиопатогенеза и клиники внутренних заболеваний

консультативно-диагностическое отделение

630089

ул. Бориса Богаткова, 175/1

Новосибирск

SB RAMS

Federal State Budgetary Institution "Research Institute of Therapy and Preventive Medicine"

630089

st. Boris Bogatkov, 175/1

Novosibirsk

Xenia_Mak@rambler.ruРАМНRAMS201308042022924762Copyright © Никитин Ю.П., Симонова Г.И., Макаренкова К.В., 20222022Никитин Ю.П., Симонова Г.И., Макаренкова К.В.Nikitin Y.P., Simonova G.I., Makarenkova K.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/677

   Одним из ведущих факторов риска атеросклероз-ассоциированных сердечно-сосудистых заболеваний, наряду с артериальной гипертонией и курением, является дислипопротеидемия. В коррекции этого фактора риска большое значение имеют не только немедикаментозные мероприятия, но и холестерин-снижающие медикаменты. Наиболее эффективными и безопасными признаются сегодня статины. Однако у некоторых больных их эффект в максимальных дозах недостаточен или сопровождается побочными эффектами. В настоящее время проходят клинические испытания несколько новых классов медикаментов: ингибиторы белка-переносчика эфиров холестерина, блокаторы синтеза апопротеина В, производные тиреоидных гормонов, разрабатываются иммунологические пути вмешательства, в частности, с помощью моноклональных антител.

   Dyslipidemia is one of the leading risk factors for atherosclerosis-associated cardiovascular disease, along with hypertension and smoking. Not only non-drug measures have great importance in the correction of this risk factor, but also cholesterol-lowering medicines. Now the statins are recognized as the most effective and safe. However, its effect of the maximum dose is insufficient or accompanied by side effects in some patients. Currently, several new classes of drugs have tested in clinical trials: cholesterol ester transfer protein inhibitors, blockers of apoprotein B synthesis, analogue of thyroid hormones; immunological intervention ways are developed, by monoclonal antibodies in particular.

коррекция дислипидемиймедикаментыcorrection of dyslipidemiamedicinesReferencesОганов Р. Г. Смертность от сердечно-сосудистых и других неинфекционных заболеваний среди трудоспособного населения России / Р. Г. Оганов, В. А. Масленникова // Кардиоваскуляр. терапия и профилактика. – 2002. – Т. 3. – С. 4–8.Оганов Р. Г. Смертность от сердечно-сосудистых и других неинфекционных заболеваний среди трудоспособного населения России / Р. Г. Оганов, В. А. Масленникова // Кардиоваскуляр. терапия и профилактика. – 2002. – Т. 3. – С. 4–8.Никитин Ю. П. Эпидемиологические аспекты терапевтических заболеваний в Новосибирске, заболеваемость, смертность и факторы риска / Ю. П. Никитин, Г. И. Симонова // Актуальная статистика Сибири. Информ.-статистич. журн. – 2012. – № 2. – С. 57–63.Никитин Ю. П. Эпидемиологические аспекты терапевтических заболеваний в Новосибирске, заболеваемость, смертность и факторы риска / Ю. П. Никитин, Г. И. Симонова // Актуальная статистика Сибири. Информ.-статистич. журн. – 2012. – № 2. – С. 57–63.Симонова Г. И. 23-летние тренды смертности в городской сибирской популяции / Г. И. Симонова [и др.] // Бюл. СО РАМН. – 2011. – Т. 31, № 1. – С. 96–101.Симонова Г. И. 23-летние тренды смертности в городской сибирской популяции / Г. И. Симонова [и др.] // Бюл. СО РАМН. – 2011. – Т. 31, № 1. – С. 96–101.Гафаров В. В. Эпидемиология и профилактика сердечно-сосудистых заболеваний в условиях крупного промышленного центра Западной Сибири / В. В. Гафаров. – Новосибирск, 1992. – 327 с.Гафаров В. В. Эпидемиология и профилактика сердечно-сосудистых заболеваний в условиях крупного промышленного центра Западной Сибири / В. В. Гафаров. – Новосибирск, 1992. – 327 с.Симонова Г. И. Хронические неинфекционные заболевания в Сибири, смертность, заболеваемость, профилактика: автореф. дис. … д-ра мед. наук / Г. И. Симонова. – Новосибирск, 1998.Симонова Г. И. Хронические неинфекционные заболевания в Сибири, смертность, заболеваемость, профилактика: автореф. дис. … д-ра мед. наук / Г. И. Симонова. – Новосибирск, 1998.Дислипидемия и атеросклероз / Ред. Р. Г. Оганов. – М.: Гэотар-Медиа, 2009. – 160 с.Дислипидемия и атеросклероз / Ред. Р. Г. Оганов. – М.: Гэотар-Медиа, 2009. – 160 с.Климов А. Н. Липиды и липопротеиды и атеросклероз / А. Н. Климов, Н. Г. Никульчева. – СПб.: Питер, 1995. – 300 с.Климов А. Н. Липиды и липопротеиды и атеросклероз / А. Н. Климов, Н. Г. Никульчева. – СПб.: Питер, 1995. – 300 с.Никитин Ю. П. Вопросы атерогенеза / Ю. П. Никитин [и др.] – Новосибирск: Ротапринт СНИИГГиМСа, 2005. – 371 с.Никитин Ю. П. Вопросы атерогенеза / Ю. П. Никитин [и др.] – Новосибирск: Ротапринт СНИИГГиМСа, 2005. – 371 с.Рагино Ю. И. Факторы и механизмы развития коронарного атеросклероза / Ю. И. Рагино. – Новосибирск: Наука, 2011. – 168 с.Рагино Ю. И. Факторы и механизмы развития коронарного атеросклероза / Ю. И. Рагино. – Новосибирск: Наука, 2011. – 168 с.Рагино Ю. И. Факторы и механизмы нестабильности атеросклеротической бляшки / Ю. И. Рагино [и др.] – Новосибирск: Наука, 2008. – 88 с.Рагино Ю. И. Факторы и механизмы нестабильности атеросклеротической бляшки / Ю. И. Рагино [и др.] – Новосибирск: Наука, 2008. – 88 с.Тот П. П. Нарушения липидного обмена / П. П. Тот, К. К. Мэки. – М.: ГЭОТАР-Медиа, 2010. – 266 с.Тот П. П. Нарушения липидного обмена / П. П. Тот, К. К. Мэки. – М.: ГЭОТАР-Медиа, 2010. – 266 с.Malyutina S., Simonova G., Nikitin Yu. Coronary Heart Disease and Cardiovascular Mortality in an Urban Siberian Population: Gender-Specific Findings from a 10-Year Cohort Study // Heart Disease: Enviroment, Stress and Gender / Ed. G. Weidner, M. Kopp, M. Kristenson.: IOS Press, 2002. 384 p.Malyutina S., Simonova G., Nikitin Yu. Coronary Heart Disease and Cardiovascular Mortality in an Urban Siberian Population: Gender-Specific Findings from a 10-Year Cohort Study // Heart Disease: Enviroment, Stress and Gender / Ed. G. Weidner, M. Kopp, M. Kristenson.: IOS Press, 2002. 384 p.Kuulasmaa K., Tunstall-Pedoe H., Dobson A. et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations // Lancet. 2000. Feb 26. Vol. 355(9205). P. 675–687.Kuulasmaa K., Tunstall-Pedoe H., Dobson A. et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations // Lancet. 2000. Feb 26. Vol. 355(9205). P. 675–687.WHO MONICA. Monograph and Multimedia Sourcebook. World’s largest study of heart disease, stroke, risk factors, and population trends 1979–2002 / Ed. Hugh Tunstall-Pedoe. WHO. 2003.WHO MONICA. Monograph and Multimedia Sourcebook. World’s largest study of heart disease, stroke, risk factors, and population trends 1979–2002 / Ed. Hugh Tunstall-Pedoe. WHO. 2003.Никитин Ю. П. Основные липидные параметры крови жителей Новосибирска / Ю. П. Никитин [и др.] // Атеросклероз. – 2012. – Т. 8, № 2. – С. 14–20.Никитин Ю. П. Основные липидные параметры крови жителей Новосибирска / Ю. П. Никитин [и др.] // Атеросклероз. – 2012. – Т. 8, № 2. – С. 14–20.Nikitin Yu., Malyutina S., Makarenkova K., Deyev A., Shalnova S. Blood lipid profile in 35-64-tear-old men in Novosibirsk and Moscow (epidemiological study) // Abstracts of the 80th EAS Congress, 26–29 may 2012. Milan, Italy.Nikitin Yu., Malyutina S., Makarenkova K., Deyev A., Shalnova S. Blood lipid profile in 35-64-tear-old men in Novosibirsk and Moscow (epidemiological study) // Abstracts of the 80th EAS Congress, 26–29 may 2012. Milan, Italy.Makarenkova K., Malyutina S., Simonova G. Nikitin Y., Bobak M. Hapiee Group. Average lipid parameters in three centers of central and eastern europe: hapiee project // Official Journal of the European Atherosclerosis Society Abstracts of the 79th EAS Congress 26−29 June, 2011, Gothenburg, Sweden. Vol. 12, N 1. P. 27.Makarenkova K., Malyutina S., Simonova G. Nikitin Y., Bobak M. Hapiee Group. Average lipid parameters in three centers of central and eastern europe: hapiee project // Official Journal of the European Atherosclerosis Society Abstracts of the 79th EAS Congress 26−29 June, 2011, Gothenburg, Sweden. Vol. 12, N 1. P. 27.Симонова Г. И. Эпидемиологические аспекты профилактики терапевтических заболеваний и снижения сверхсмертности населения Сибири / Г. И. Симонова // Журн. эксперимент. и клинич. медицины. – 2004. – № 4. – С. 71–75.Симонова Г. И. Эпидемиологические аспекты профилактики терапевтических заболеваний и снижения сверхсмертности населения Сибири / Г. И. Симонова // Журн. эксперимент. и клинич. медицины. – 2004. – № 4. – С. 71–75.Симонова Г. И. Питание и атеросклероз / Г. И. Симонова, В. А. Тутельян, А. В. Погожева // Бюл. СО РАМН. – 2006. – № 2. – С. 60–65.Симонова Г. И. Питание и атеросклероз / Г. И. Симонова, В. А. Тутельян, А. В. Погожева // Бюл. СО РАМН. – 2006. – № 2. – С. 60–65.Симонова Г. И. Фактическое питание и здоровье населения Сибири: результаты двадцатилетних эпидемиологических исследований / Г. И. Симонова [и др.] // Бюл. СО РАМН. – 2006. – № 4. – С. 22–30.Симонова Г. И. Фактическое питание и здоровье населения Сибири: результаты двадцатилетних эпидемиологических исследований / Г. И. Симонова [и др.] // Бюл. СО РАМН. – 2006. – № 4. – С. 22–30.Российские рекомендации ВНОК. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза (IV и V пересмотра) // Кардиоваскуляр. терапия и профилактика. – 2009. – № 8. – Прил. 3. – С. 58. – Рос. кардиол. журн. – Прил. 1. – 2012. – Т. 4 (96). – 32 с.Российские рекомендации ВНОК. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза (IV и V пересмотра) // Кардиоваскуляр. терапия и профилактика. – 2009. – № 8. – Прил. 3. – С. 58. – Рос. кардиол. журн. – Прил. 1. – 2012. – Т. 4 (96). – 32 с.Руководство по лечению дислипидемий Европейского общества кардиологов и Европейского общества атеросклероза // Атеросклероз и дислипидемии. – 2011. – № 4. – C. 4–72.Руководство по лечению дислипидемий Европейского общества кардиологов и Европейского общества атеросклероза // Атеросклероз и дислипидемии. – 2011. – № 4. – C. 4–72.Шевченко О. П. Ишемическая болезнь сердца / О. П. Шевченко, О. Д. Мишнев. – М.: Реафарм, 2005. – 416 с.Шевченко О. П. Ишемическая болезнь сердца / О. П. Шевченко, О. Д. Мишнев. – М.: Реафарм, 2005. – 416 с.Шевченко О. П. Статины ингибиторы ГМГ–КоА–редуктазы / О. П. Шевченко, А. О. Шевченко. – М.: Реафарм, 2003. – 112 с.Шевченко О. П. Статины ингибиторы ГМГ–КоА–редуктазы / О. П. Шевченко, А. О. Шевченко. – М.: Реафарм, 2003. – 112 с.Kwiterovich P. O. The Johns Hopkins Textbook of Dyslipidemia. Philadelphia: LWW.com, 2010.Kwiterovich P. O. The Johns Hopkins Textbook of Dyslipidemia. Philadelphia: LWW.com, 2010.Welder G., Zineh I., Pacanowski M. A. et al. High dose atorvastatin causes a rapid, sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol // J. Lipid Res. 2010. Vol. 5. P. 2714–2721.Welder G., Zineh I., Pacanowski M. A. et al. High dose atorvastatin causes a rapid, sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol // J. Lipid Res. 2010. Vol. 5. P. 2714–2721.Титов В. Н. Семейная гиперхолестеринемия / В. Н. Титов, Х. Г. Алиджанова, П. П. Малышев. – М.: БИНОМ, 2011.Титов В. Н. Семейная гиперхолестеринемия / В. Н. Титов, Х. Г. Алиджанова, П. П. Малышев. – М.: БИНОМ, 2011.Перова Н. В. Нарушения липидного обмена, их диагностика и коррекция / Н. В. Перова; ред. Р. Г. Оганов // Болезни сердца. – М.: Литера, 2006. – С. 205–217.Перова Н. В. Нарушения липидного обмена, их диагностика и коррекция / Н. В. Перова; ред. Р. Г. Оганов // Болезни сердца. – М.: Литера, 2006. – С. 205–217.Hyan Y. J., Kim O. Y., Kang J. B. et al. Plant stanol esters in low-fat yoghurt reduces total and low-density lipoprotein oxidation in normocholesterolaemic and mildly hypercholesterolaemic subjects // Nutritional Research. 2006. Vol. 25. P. 743–753.Hyan Y. J., Kim O. Y., Kang J. B. et al. Plant stanol esters in low-fat yoghurt reduces total and low-density lipoprotein oxidation in normocholesterolaemic and mildly hypercholesterolaemic subjects // Nutritional Research. 2006. Vol. 25. P. 743–753.Korpela R., Tuomilehto J., Hogstrom R. et al. Safety aspects and cholesterol-lowering efficacy of low fat dairy products containing plant sterol // Eur. J. Clin. Nutr. 2006. Vol. 60. P. 633–642.Korpela R., Tuomilehto J., Hogstrom R. et al. Safety aspects and cholesterol-lowering efficacy of low fat dairy products containing plant sterol // Eur. J. Clin. Nutr. 2006. Vol. 60. P. 633–642.Thompson G. R., Grundy S. M. History and development of plant sterol and stanol esters for cholesterol-lowering purposes // Am. J. Cardiol. 2005. Vol. 1A. P. 3D–9D.Thompson G. R., Grundy S. M. History and development of plant sterol and stanol esters for cholesterol-lowering purposes // Am. J. Cardiol. 2005. Vol. 1A. P. 3D–9D.Лякишев А. А. Перспективы применения эзетимиба в кардиологической практике / А. А. Лякишев, А. Е. Семенова, С. В. Миклишанеская // Атеросклероз и дислипидемии. – 2010. – № 1. – С. 50–54.Лякишев А. А. Перспективы применения эзетимиба в кардиологической практике / А. А. Лякишев, А. Е. Семенова, С. В. Миклишанеская // Атеросклероз и дислипидемии. – 2010. – № 1. – С. 50–54.Mikhailidis D. P., Wierzbicki A. S., Daskalopoulou S. S. et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position of a United Kingdom consensus panel // Curr. Med. Res. Opin. 2005. Vol. 21, N 6. P. 959–969.Mikhailidis D. P., Wierzbicki A. S., Daskalopoulou S. S. et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position of a United Kingdom consensus panel // Curr. Med. Res. Opin. 2005. Vol. 21, N 6. P. 959–969.Murdoch D., Scott L. J. Ezetimibe / Simvastatin. A review of its Use in the Management of Hypercholesterolemia // Am. J. Cardiovasc. Drugs. 2004. Vol. 4, N 6. P. 405–422.Murdoch D., Scott L. J. Ezetimibe / Simvastatin. A review of its Use in the Management of Hypercholesterolemia // Am. J. Cardiovasc. Drugs. 2004. Vol. 4, N 6. P. 405–422.Thomas A. Pearson, Margo A. Denke, Patrick E. McBride et al. A community-Based, Randomized Trial of Ezetimibe Added to Statin Therapy to Attain NCEP ATP III Goals for LDL Cholesterol in Hypercholes-terolemic Patients: The Ezetimibe Add-On to Statin Effectiveness (EASE) Trial // Mayo Clin. Proc. 2005. Vol. 80, N 5. P. 587–595.Thomas A. Pearson, Margo A. Denke, Patrick E. McBride et al. A community-Based, Randomized Trial of Ezetimibe Added to Statin Therapy to Attain NCEP ATP III Goals for LDL Cholesterol in Hypercholes-terolemic Patients: The Ezetimibe Add-On to Statin Effectiveness (EASE) Trial // Mayo Clin. Proc. 2005. Vol. 80, N 5. P. 587–595.Rossebo A. B., Pederson T. R., Boman K. et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis // N. Engl. J. Med. 2008. Vol. 359. P. 1343–1356.Rossebo A. B., Pederson T. R., Boman K. et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis // N. Engl. J. Med. 2008. Vol. 359. P. 1343–1356.Peto R., Emberson J., Landray M. et al. Analyses of cancer data from three ezetimibeb trials // N. Engl. J. Med. 2008. Vol. 359. P. 1357–1366.Peto R., Emberson J., Landray M. et al. Analyses of cancer data from three ezetimibeb trials // N. Engl. J. Med. 2008. Vol. 359. P. 1357–1366.Duntas L. H. Thyroid disease and lipids // Thyroid. 2002. Apr. Vol. 12, N 4. P. 287–293.Duntas L. H. Thyroid disease and lipids // Thyroid. 2002. Apr. Vol. 12, N 4. P. 287–293.Дедов И. И. Эндокринология / И. И. Дедов, Г. А. Мельниченко, В. Ф. Фадеев. – М.: ГЭОТАР-Медиа, 2007. – 432 c.Дедов И. И. Эндокринология / И. И. Дедов, Г. А. Мельниченко, В. Ф. Фадеев. – М.: ГЭОТАР-Медиа, 2007. – 432 c.Strisower E. H., Strisower B. The separate hypolipoproteinemic effects of dextrothyroxine and ethyl chlorophenoxyisobutirate // J. Clin. Endocrinol. Metab. 1964. Vol. 24. P. 139–144.Strisower E. H., Strisower B. The separate hypolipoproteinemic effects of dextrothyroxine and ethyl chlorophenoxyisobutirate // J. Clin. Endocrinol. Metab. 1964. Vol. 24. P. 139–144.Sherman S. I., Ringel M. D., Smith M. J. et al. Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine // J. Clin. Endocrinol. Metab. 1997. Vol. 82. P. 2153–2158.Sherman S. I., Ringel M. D., Smith M. J. et al. Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine // J. Clin. Endocrinol. Metab. 1997. Vol. 82. P. 2153–2158.Berkenstam A., Kristensen J., Mellstrom K. et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans // Proc. Natl. Acad. Sci. USA. 2008. Vol. 105. P. 663–667.Berkenstam A., Kristensen J., Mellstrom K. et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans // Proc. Natl. Acad. Sci. USA. 2008. Vol. 105. P. 663–667.Morkin E., Pennock G., Spoonet P. H. et al. Pilot studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure // Cardiology. 2002. Vol. 97. P. 218–225.Morkin E., Pennock G., Spoonet P. H. et al. Pilot studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure // Cardiology. 2002. Vol. 97. P. 218–225.Grover G. J., Mellstrom K., Ye L. et al. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein(a) with reduced cardiovascular liability // Proc. Natl. Acad. Sci. USA. 2003. Vol. 100. P. 10067–10072.Grover G. J., Mellstrom K., Ye L. et al. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein(a) with reduced cardiovascular liability // Proc. Natl. Acad. Sci. USA. 2003. Vol. 100. P. 10067–10072.Angelin B., Rudling M. Lipid lowering with thyroid hormone and thyromimetics // Curr. Opin. Lipidol. 2010. Vol. 21, N 6. P. 499–506.Angelin B., Rudling M. Lipid lowering with thyroid hormone and thyromimetics // Curr. Opin. Lipidol. 2010. Vol. 21, N 6. P. 499–506.Webb P. Thyroid hormone receptor and lipid regulation // Curr. Opin. Investig. Drugs. 2010. Oct 11. (10). P. 1135–1142.Webb P. Thyroid hormone receptor and lipid regulation // Curr. Opin. Investig. Drugs. 2010. Oct 11. (10). P. 1135–1142.Ness G. C., Pendleton L. C., Li Y. C., Chiang I. Y. Effect of thyroid hormone on hepatic cholesterol 7 alpha hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats // Biochem. Biophys. Res. Commun. 1990. Vol. 172. P. 1150–1156.Ness G. C., Pendleton L. C., Li Y. C., Chiang I. Y. Effect of thyroid hormone on hepatic cholesterol 7 alpha hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats // Biochem. Biophys. Res. Commun. 1990. Vol. 172. P. 1150–1156.Gullberg H., Rudling M., Salto C., Forrest D., Angelin B., Vennstrom B. Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol metabolism in mice // Mol. Endocrinol. 2002. Vol. 16. P. 1767–1777.Gullberg H., Rudling M., Salto C., Forrest D., Angelin B., Vennstrom B. Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol metabolism in mice // Mol. Endocrinol. 2002. Vol. 16. P. 1767–1777.Day R., Gebhard R. L., Schwartz H. L. et al. Time course of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and messenger ribonucleic acid, biliary lipid secretion, and hepatic cholesterol content in methimazole-treated hypothyroid and hypophysectomized rats after triiodothyronine administration: possible linkage of cholesterol synthesis to biliary secretion // Endocrinology. 1989. Vol. 125. P. 459–468.Day R., Gebhard R. L., Schwartz H. L. et al. Time course of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and messenger ribonucleic acid, biliary lipid secretion, and hepatic cholesterol content in methimazole-treated hypothyroid and hypophysectomized rats after triiodothyronine administration: possible linkage of cholesterol synthesis to biliary secretion // Endocrinology. 1989. Vol. 125. P. 459–468.Landenson P. W., McCarren M., Morkin E. et al. Effects of the thyromimetic agent diiodothyropropionic acid (DITPA) on body weight, BMI, and serum lipoprotein: a pilot prospective, randomized, controlled study // J. Clin. Endocrinol. Metab. 2010. Vol. 95. P. 349–354.Landenson P. W., McCarren M., Morkin E. et al. Effects of the thyromimetic agent diiodothyropropionic acid (DITPA) on body weight, BMI, and serum lipoprotein: a pilot prospective, randomized, controlled study // J. Clin. Endocrinol. Metab. 2010. Vol. 95. P. 349–354.Landenson P. W., Kristensen J. D., Ridgway E. C., Olsson A. G., Carlsson B., Klein I., Baxter J., Angelin B. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia // N. Engl. J. Med. 2010. Mar. 11. Vol. 362, N 10. P. 906–916.Landenson P. W., Kristensen J. D., Ridgway E. C., Olsson A. G., Carlsson B., Klein I., Baxter J., Angelin B. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia // N. Engl. J. Med. 2010. Mar. 11. Vol. 362, N 10. P. 906–916.Koch L. Lipids: Eprotirome shows promise as a novel way to target dyslipidemia // Nat. Rev. Endocrinol. 2010. Jul. Vol. 6, N 7. P. 354.Koch L. Lipids: Eprotirome shows promise as a novel way to target dyslipidemia // Nat. Rev. Endocrinol. 2010. Jul. Vol. 6, N 7. P. 354.Shoemaker T. J., Kono T., Mariash C. N., Evans-Molina C. Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs? // Endocrinol. Pract. 2012. Nov.-Dec. Vol. 18, N 6. P. 954–964.Shoemaker T. J., Kono T., Mariash C. N., Evans-Molina C. Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs? // Endocrinol. Pract. 2012. Nov.-Dec. Vol. 18, N 6. P. 954–964.KaroBio. – Информационное письмо от 16. 02. 2012 о прекращении исследования KBT 009.KaroBio. – Информационное письмо от 16. 02. 2012 о прекращении исследования KBT 009.Сlofi F., Lanni A., Goglia F. Thyroid hormones, mitochondrial bioenergetics and lipid handling // Curr. Opin. Endocrinol. Diabetes. Obes. 2010. Oct. Vol. 17, N 5. P. 402–407.Сlofi F., Lanni A., Goglia F. Thyroid hormones, mitochondrial bioenergetics and lipid handling // Curr. Opin. Endocrinol. Diabetes. Obes. 2010. Oct. Vol. 17, N 5. P. 402–407.Nissen S. E., Tsunoda T., Tuzcu E. M. et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial // JAMA. 2003. Nov. 5. Vol. 290, N 17. P. 2292–2300.Nissen S. E., Tsunoda T., Tuzcu E. M. et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial // JAMA. 2003. Nov. 5. Vol. 290, N 17. P. 2292–2300.Поляков Л. М. Липопротеины высокой плотности и апопротеин А-I: регуляторная роль и новые терапевтические стратегии лечения атеросклероза / Л. М. Поляков, Л. М. Панин // Атеросклероз. – 2013. – Т. 9, № 1. – С. 42–53.Поляков Л. М. Липопротеины высокой плотности и апопротеин А-I: регуляторная роль и новые терапевтические стратегии лечения атеросклероза / Л. М. Поляков, Л. М. Панин // Атеросклероз. – 2013. – Т. 9, № 1. – С. 42–53.Barter P. J., Rye K. A. Current status and future direction // Sherborne Gibbs Limited. Birmingham. UK. 2008. P. 1–51.Barter P. J., Rye K. A. Current status and future direction // Sherborne Gibbs Limited. Birmingham. UK. 2008. P. 1–51.Alan R. Tall, Laurent Yvan-Charvet, Nan Wang. The Failure of Torcetrapib. Was it the Molecule or the Mechanism? // Arteriosclerosis, Thrombosis, and Vascular Biology. 2007. Vol. 27. P. 257–260Alan R. Tall, Laurent Yvan-Charvet, Nan Wang. The Failure of Torcetrapib. Was it the Molecule or the Mechanism? // Arteriosclerosis, Thrombosis, and Vascular Biology. 2007. Vol. 27. P. 257–260Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial // Am. J. Cardiol. 2009. Nov 16. Vol. 104 (10 Suppl). P. 10E-5E.Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial // Am. J. Cardiol. 2009. Nov 16. Vol. 104 (10 Suppl). P. 10E-5E.Rensen P. C., Jukema J. W. [Torcetrapib increases mortality in patients with a high risk of cardiovascular disorders] // Ned. Tijdschr. Geneeskd. 2008. May 10. Vol. 152, N 19. P. 1088–1090.Rensen P. C., Jukema J. W. [Torcetrapib increases mortality in patients with a high risk of cardiovascular disorders] // Ned. Tijdschr. Geneeskd. 2008. May 10. Vol. 152, N 19. P. 1088–1090.Blasi E., Bamberger M., Knight D. et al. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure // J. Cardiovasc. Pharmacol. 2009. Jun. Vol. 53, N 6. P. 507–516.Blasi E., Bamberger M., Knight D. et al. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure // J. Cardiovasc. Pharmacol. 2009. Jun. Vol. 53, N 6. P. 507–516.Hu X., Dietz J. D., Xia C. et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition // Endocrinology. 2009. May. Vol. 150, N 5. P. 2211–2219.Hu X., Dietz J. D., Xia C. et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition // Endocrinology. 2009. May. Vol. 150, N 5. P. 2211–2219.Kastelein J. J., van Leuven S. I., Burgess L. et al. RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia // N. Engl. J. Med. 2007. Apr. 19. Vol. 356, N 16. P. 1620–1630.Kastelein J. J., van Leuven S. I., Burgess L. et al. RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia // N. Engl. J. Med. 2007. Apr. 19. Vol. 356, N 16. P. 1620–1630.Dogan S., Duivenvoorden R., Grobbee D. E. et al. Radiance 1 and Radiance 2 Study Groups. Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia // Ann. Med. 2010. Sep. Vol. 42, N 6. P. 447–464.Dogan S., Duivenvoorden R., Grobbee D. E. et al. Radiance 1 and Radiance 2 Study Groups. Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia // Ann. Med. 2010. Sep. Vol. 42, N 6. P. 447–464.Bots M. L., Visseren F. L., Evans G. W. et al. RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial // Lancet. 2007. Jul 14. Vol. 370 (9582). P. 153–160.Bots M. L., Visseren F. L., Evans G. W. et al. RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial // Lancet. 2007. Jul 14. Vol. 370 (9582). P. 153–160.Paolillo S., Della Ratta G. L., Vitagliano A. et al. New perspectives in cardiovascular risk reduction: focus on HDL // Monaldi Arch. Chest. Dis. 2013. Mar. Vol. 80, N 1. P. 27–30.Paolillo S., Della Ratta G. L., Vitagliano A. et al. New perspectives in cardiovascular risk reduction: focus on HDL // Monaldi Arch. Chest. Dis. 2013. Mar. Vol. 80, N 1. P. 27–30.Robinson J. G. Dalcetrapib: a review of Phase II data // Expert. Opin. Investig. Drugs. 2010. Jun. Vol. 19, N 6. P. 795–805.Robinson J. G. Dalcetrapib: a review of Phase II data // Expert. Opin. Investig. Drugs. 2010. Jun. Vol. 19, N 6. P. 795–805.Luscher T. F., Taddei S., Kaski J. C. et al. dal-VESSEL Investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial // Eur. Heart J. 2012. Apr. Vol. 33, N 7. P. 857–865.Luscher T. F., Taddei S., Kaski J. C. et al. dal-VESSEL Investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial // Eur. Heart J. 2012. Apr. Vol. 33, N 7. P. 857–865.Fayad Z. A., Mani V., Woodward M. et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial // Lancet. 2011. Oct. 29. Vol. 378. (9802). P. 1547–1559.Fayad Z. A., Mani V., Woodward M. et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial // Lancet. 2011. Oct. 29. Vol. 378. (9802). P. 1547–1559.Landmesser U., von Eckardstein A., Kastelein J. et al. CEPT-inhibition: lessons from the halted dal-HEART programme // Eur. Heart J. 2012. N 13.Landmesser U., von Eckardstein A., Kastelein J. et al. CEPT-inhibition: lessons from the halted dal-HEART programme // Eur. Heart J. 2012. N 13.Schwartz G. G., Olsson A. G., Ballantyne C. M. et al. dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome // Am. Heart J. 2009. Dec. 158, N 6. P. 896–901.Schwartz G. G., Olsson A. G., Ballantyne C. M. et al. dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome // Am. Heart J. 2009. Dec. 158, N 6. P. 896–901.Schwartz G. G., Olsson A. G., Abt M. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome // N. Engl. J. Med. 2012. Nov. 29. Vol. 367, N 22. P. 2089–2099.Schwartz G. G., Olsson A. G., Abt M. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome // N. Engl. J. Med. 2012. Nov. 29. Vol. 367, N 22. P. 2089–2099.Tomoda H. N. Dalcetrapib in patients with an acute coronary syndrome // Engl. J. Med. 2013. Feb. 28. Vol. 368, N 9. P. 869.Tomoda H. N. Dalcetrapib in patients with an acute coronary syndrome // Engl. J. Med. 2013. Feb. 28. Vol. 368, N 9. P. 869.Гуревич В. С. Эволюция представлений о про- и антиатерогенных свойствах липопротеинов / В. С. Гуревич [и др.] // Атеросклероз и дислипидемии. – 2012. – № 4. – С. 52–61.Гуревич В. С. Эволюция представлений о про- и антиатерогенных свойствах липопротеинов / В. С. Гуревич [и др.] // Атеросклероз и дислипидемии. – 2012. – № 4. – С. 52–61.Voight B. F., Peloso G. M., Orbo-Melander M. et al. Plasma HDL cholesterol and risk of myocardial infarction a mendelian randomization study // The Lancet published online. 2012. May 17.Voight B. F., Peloso G. M., Orbo-Melander M. et al. Plasma HDL cholesterol and risk of myocardial infarction a mendelian randomization study // The Lancet published online. 2012. May 17.Cannon C. P., Shah S., Dansky H. M. Safety of Anacetrapib in patients with or at high risk for coronary heart disease // N. Engl. J. Med. 2010. Vol. 363. P. 2406–2415.Cannon C. P., Shah S., Dansky H. M. Safety of Anacetrapib in patients with or at high risk for coronary heart disease // N. Engl. J. Med. 2010. Vol. 363. P. 2406–2415.Lewis C. E. Defining the Safety of Anacetrapib, a CETP Inhibitor, in Patients at High Risk for Coronary Heart Disease: the DEFINE study // Curr. Cardiovasc. Risk. Rep. 2011. Apr. Vol. 5, N 2. P. 109–112.Lewis C. E. Defining the Safety of Anacetrapib, a CETP Inhibitor, in Patients at High Risk for Coronary Heart Disease: the DEFINE study // Curr. Cardiovasc. Risk. Rep. 2011. Apr. Vol. 5, N 2. P. 109–112.Hooper A. J., Burnett J. R. Anacetrapib, a cholesteryl ester transfer protein inhibitor // Expert. Opin. Investig. Drugs. 2012. Jan. Vol. 21, N 1. P. 103–109.Hooper A. J., Burnett J. R. Anacetrapib, a cholesteryl ester transfer protein inhibitor // Expert. Opin. Investig. Drugs. 2012. Jan. Vol. 21, N 1. P. 103–109.Gotto A. M. Jr., Moon J. E. Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study // Expert. Rev. Cardiovasc. Ther. 2012. Aug. Vol. 10, N 8. P. 955–963.Gotto A. M. Jr., Moon J. E. Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study // Expert. Rev. Cardiovasc. Ther. 2012. Aug. Vol. 10, N 8. P. 955–963.Davidson M., Liu S. X., Barter P. et al. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib // J. Lipid. Res. 2013. Feb. Vol. 54, N 2. P. 467–472.Davidson M., Liu S. X., Barter P. et al. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib // J. Lipid. Res. 2013. Feb. Vol. 54, N 2. P. 467–472.Teramoto T., Shirakawa M., Kikuchi M. et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia // Atherosclerosis. 2013. Sep. Vol. 230, N 1. P. 52–60.Teramoto T., Shirakawa M., Kikuchi M. et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia // Atherosclerosis. 2013. Sep. Vol. 230, N 1. P. 52–60.Miyares M. A., Davis K. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib // Vasc. Health Risk. Manag. 2012. Vol. 8. P. 483–493.Miyares M. A., Davis K. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib // Vasc. Health Risk. Manag. 2012. Vol. 8. P. 483–493.Presentation Roshe / Investor science conference call from ESC 2011 Paris, 29 August 2011, https://lemediascope.fr/roche-roche-investor-science-call-from-esc-2011/Presentation Roshe / Investor science conference call from ESC 2011 Paris, 29 August 2011, https://lemediascope.fr/roche-roche-investor-science-call-from-esc-2011/Horowitz J. D., Rosenson R. S., McMurray J. J. et al. Clinical Trials Update AHA Congress 2010 // Cardiovasc. Drugs. Ther. 2011. Feb. Vol. 25, N 1. P. 69–76.Horowitz J. D., Rosenson R. S., McMurray J. J. et al. Clinical Trials Update AHA Congress 2010 // Cardiovasc. Drugs. Ther. 2011. Feb. Vol. 25, N 1. P. 69–76.Shinkai H. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases // Vasc. Health. Risk. Manag. 2012. Vol. 8. P. 323–331.Shinkai H. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases // Vasc. Health. Risk. Manag. 2012. Vol. 8. P. 323–331.Hewing B., Fisher E. A. Rationale for cholesteryl ester transfer protein inhibition // Curr. Opin. Lipidol. 2012. Aug. Vol. 23, N 4. P. 372–376.Hewing B., Fisher E. A. Rationale for cholesteryl ester transfer protein inhibition // Curr. Opin. Lipidol. 2012. Aug. Vol. 23, N 4. P. 372–376.Cao G., Beyer T. P., Zhang Y., Schmidt R. J. et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure // J. Lipid. Res. 2011. Dec. 52, N 12. P. 2169–2176.Cao G., Beyer T. P., Zhang Y., Schmidt R. J. et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure // J. Lipid. Res. 2011. Dec. 52, N 12. P. 2169–2176.Mearns B. M. Pharmacotherapy: Beneficial effects of evacetrapib // Nat. Rev. Cardiol. 2011. Nov. 29. Vol. 9, N 1. P. 6.Mearns B. M. Pharmacotherapy: Beneficial effects of evacetrapib // Nat. Rev. Cardiol. 2011. Nov. 29. Vol. 9, N 1. P. 6.Steen D. L., Cannon C. P. Atherosclerosis. Effects of evacetrapib administered as monotherapy or in combination with statins // Rev. Cardiovasc. Med. 2012. Vol. 13, N 1. P. e48–е51.Steen D. L., Cannon C. P. Atherosclerosis. Effects of evacetrapib administered as monotherapy or in combination with statins // Rev. Cardiovasc. Med. 2012. Vol. 13, N 1. P. e48–е51.Nicholls S. J. Evacetrapib // Curr. Cardiol. Rep. 2012. Jun. Vol. 14, N 3. P. 245–250.Nicholls S. J. Evacetrapib // Curr. Cardiol. Rep. 2012. Jun. Vol. 14, N 3. P. 245–250.http://clinicaltrials.gov/show/NCT01687998 или https://www.researchgate.net/publication/334154026_Evidence-based_treatments_for_rosacea_based_on_phenotype_approachhttp://clinicaltrials.gov/show/NCT01687998 или https://www.researchgate.net/publication/334154026_Evidence-based_treatments_for_rosacea_based_on_phenotype_approachJamil H. D., Gordon A. An inhibitior of microsomal trigliceride transfer protein inhibits apoB secretion from HepG2 cells // Proc. of the National Academy of Sciences of the United States of America. 1996. Vol. 93, N 21. P. 11991–11995.Jamil H. D., Gordon A. An inhibitior of microsomal trigliceride transfer protein inhibits apoB secretion from HepG2 cells // Proc. of the National Academy of Sciences of the United States of America. 1996. Vol. 93, N 21. P. 11991–11995.Liao W., Hui T. Y. Blocking microsomal trigliceride transfer protein interferes with apoB secretion without causing retention or stress in the ER // J. Lipid Res. 2003. Vol. 44, N 5. P. 978–985.Liao W., Hui T. Y. Blocking microsomal trigliceride transfer protein interferes with apoB secretion without causing retention or stress in the ER // J. Lipid Res. 2003. Vol. 44, N 5. P. 978–985.Rizzo M. Lomitapide, a microsomal trigliceride transfer protein inhibitor for treatment of hypercholesterolemia // Drugs. 2010. Feb. 13, N 2. P. 103–111.Rizzo M. Lomitapide, a microsomal trigliceride transfer protein inhibitor for treatment of hypercholesterolemia // Drugs. 2010. Feb. 13, N 2. P. 103–111.Perry C. M. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia // Am. J. Cardiovasc. Drugs. 2013. Aug. Vol. 13, N 4. P. 285–296.Perry C. M. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia // Am. J. Cardiovasc. Drugs. 2013. Aug. Vol. 13, N 4. P. 285–296.Raal F. G. Lomitapide for homozygous familial hypercholesterolemia // Lancet. 2013. Jan. 5. Vol. 381 (9860). P. 7–8.Raal F. G. Lomitapide for homozygous familial hypercholesterolemia // Lancet. 2013. Jan. 5. Vol. 381 (9860). P. 7–8.Athyros V. G., Kakafika A. I., Tziomalos K. et al. Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster? // Expert Opin Investig Drugs. 2008. Vol. 17, N 7. P. 969–972.Athyros V. G., Kakafika A. I., Tziomalos K. et al. Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster? // Expert Opin Investig Drugs. 2008. Vol. 17, N 7. P. 969–972.Merki E., Graham M. J., Mullick A. E. et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice // Circulation. 2008. Vol. 118, N 7. P. 743–753.Merki E., Graham M. J., Mullick A. E. et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice // Circulation. 2008. Vol. 118, N 7. P. 743–753.Akdim F., Stroes E. S., Sijbrands E. J. et al. Effi cacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy // J. Am. Coll. Cardiol. 2010. Apr. 13. Vol. 55, N 15. P. 1611–1618.Akdim F., Stroes E. S., Sijbrands E. J. et al. Effi cacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy // J. Am. Coll. Cardiol. 2010. Apr. 13. Vol. 55, N 15. P. 1611–1618.Hovingh K., Besseling J., Kastelein J. Efficacy and safety of mipomersen sodium (Kynamro) // Expert. Opin. Drug. Saf. 2013. Jul. Vol. 12, N 4. P. 569–579.Hovingh K., Besseling J., Kastelein J. Efficacy and safety of mipomersen sodium (Kynamro) // Expert. Opin. Drug. Saf. 2013. Jul. Vol. 12, N 4. P. 569–579.Raal F. J., Santos R. D., Blom D. J. et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial // Lancet. 2010. Mar. 20. Vol. 375 (9719). P. 998–1006.Raal F. J., Santos R. D., Blom D. J. et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial // Lancet. 2010. Mar. 20. Vol. 375 (9719). P. 998–1006.Thomas G. S., Cromwell W. C., Ali S. et al. Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients with Severe Hypercholesterolemia at High Cardiovascular Risk: A Randomized, Double-Blind, Placebo-Controlled Trial // J. Am. Coll. Cardiol. 2013. Aug 30. pii: S0735-1097(13)04044-8.Thomas G. S., Cromwell W. C., Ali S. et al. Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients with Severe Hypercholesterolemia at High Cardiovascular Risk: A Randomized, Double-Blind, Placebo-Controlled Trial // J. Am. Coll. Cardiol. 2013. Aug 30. pii: S0735-1097(13)04044-8.https://www.fda.gov/media/99984/downloadhttps://www.fda.gov/media/99984/downloadhttp://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002429/WC500136279.pdfhttp://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002429/WC500136279.pdfHarchaoui K., Akdim F., Stroes E. S. et al. Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins // Am. J. Cardiovasc. Drugs. 2008. Vol. 8, N 4. P. 233–242.Harchaoui K., Akdim F., Stroes E. S. et al. Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins // Am. J. Cardiovasc. Drugs. 2008. Vol. 8, N 4. P. 233–242.Lambert G., Charlton F., Rye K.-A. et al. Molecular basis of PCSK9 Function // Atherosclerosis. 2009. Vol. 203. P. 1–7.Lambert G., Charlton F., Rye K.-A. et al. Molecular basis of PCSK9 Function // Atherosclerosis. 2009. Vol. 203. P. 1–7.Cunningham D., Danley D. E., Geoghegan K. F. et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia // Nat. Struct. Mol. Biol. 2007. Vol. 14, N 5. P. 413–419.Cunningham D., Danley D. E., Geoghegan K. F. et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia // Nat. Struct. Mol. Biol. 2007. Vol. 14, N 5. P. 413–419.Piper D. E., Jackson S., Liu Q., Romanow W. G., Shetterly S., Thibault S. T. et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol // Structure. 2007. Vol. 15, N 5. P. 545–552.Piper D. E., Jackson S., Liu Q., Romanow W. G., Shetterly S., Thibault S. T. et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol // Structure. 2007. Vol. 15, N 5. P. 545–552.McNutt M. C., Lagace A., Horton J. D. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells // J. Biol. Chem. 2007. Vol. 282, N 29. P. 20799–20803.McNutt M. C., Lagace A., Horton J. D. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells // J. Biol. Chem. 2007. Vol. 282, N 29. P. 20799–20803.Grundy S. M., Deedwania P., Barter P. et al. Reduction of low density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome. Analysis of the Treating to New Targets study // Lancet. 2006. Vol. 368 (9539). P. 919–928.Grundy S. M., Deedwania P., Barter P. et al. Reduction of low density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome. Analysis of the Treating to New Targets study // Lancet. 2006. Vol. 368 (9539). P. 919–928.Urban D., Pöss J., Böhm M., Laufs U. Targeting the proprotein convertase subtilisin/kexin type 9 (PCSK9) for the treatment of dyslipidemia and atherosclerosis // J. Am. Coll. Cardiol. 2013. Aug 12.Urban D., Pöss J., Böhm M., Laufs U. Targeting the proprotein convertase subtilisin/kexin type 9 (PCSK9) for the treatment of dyslipidemia and atherosclerosis // J. Am. Coll. Cardiol. 2013. Aug 12.Hooper A. J., Marais A. D., Tanyanyiwa D. M., Burnett J. R. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population // Atherosclerosis. 2007. Vol. 193. N 2. P. 445–448.Hooper A. J., Marais A. D., Tanyanyiwa D. M., Burnett J. R. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population // Atherosclerosis. 2007. Vol. 193. N 2. P. 445–448.Zhao Z., Tuakli-Wosornu Y., Lagace T. A. et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote // Am. J. Hum. Genet. 2006. Vol. 79. P. 514–523.Zhao Z., Tuakli-Wosornu Y., Lagace T. A. et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote // Am. J. Hum. Genet. 2006. Vol. 79. P. 514–523.Cariou B., Ouguerram K., Zair Y. et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia // Arterioscler. Thromb. Vasc. Biol. 2009. Vol. 29, N 12. P. 2191–2197.Cariou B., Ouguerram K., Zair Y. et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia // Arterioscler. Thromb. Vasc. Biol. 2009. Vol. 29, N 12. P. 2191–2197.Cohen J. C., Boerwinkle E., Mosley T. H., Hobbs H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease // N. Engl. J. Med. 2006. Vol. 354, N 12. P. 1264–1272.Cohen J. C., Boerwinkle E., Mosley T. H., Hobbs H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease // N. Engl. J. Med. 2006. Vol. 354, N 12. P. 1264–1272.Abifadel M., Varret M., Rabes J.P., Allard D., Ouguerram K., Devillers M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia // Nat Genet. 2003. Vol. 34, N 2. P. 154–156.Abifadel M., Varret M., Rabes J.P., Allard D., Ouguerram K., Devillers M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia // Nat Genet. 2003. Vol. 34, N 2. P. 154–156.Abifadel M., Rabs J. P., Devillers M. et al. Mutations and polymorphisms in the proprotein convertase, subtilisin/kexin type 9 (PCSK9) gene in cholesterol metabolism and disease // Hum. Mutat. 2008. Vol. 30, N 4. P. 1–11.Abifadel M., Rabs J. P., Devillers M. et al. Mutations and polymorphisms in the proprotein convertase, subtilisin/kexin type 9 (PCSK9) gene in cholesterol metabolism and disease // Hum. Mutat. 2008. Vol. 30, N 4. P. 1–11.Stein E. A., Mellis S., Yancoupoloulos G. D. et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol // N. Engl. J. Med. 2012. Vol. 366. P. 1108–1118.Stein E. A., Mellis S., Yancoupoloulos G. D. et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol // N. Engl. J. Med. 2012. Vol. 366. P. 1108–1118.McKenney J. M., Koren M. J., Kereiakes D. J. et al. Safety and efficiency of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR 236553/REGN 727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy // Am. Coll. Cardiol. 2012. Vol. 59. P. 2344–2353.McKenney J. M., Koren M. J., Kereiakes D. J. et al. Safety and efficiency of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR 236553/REGN 727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy // Am. Coll. Cardiol. 2012. Vol. 59. P. 2344–2353.Roth E. M., McKenney J. M., Hanotin C. et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia // N. Engl. J. Med. 2012. Vol. 367, N 20. P. 1891–1900.Roth E. M., McKenney J. M., Hanotin C. et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia // N. Engl. J. Med. 2012. Vol. 367, N 20. P. 1891–1900.Stein E. A., Gipe D., Bergeron J. et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial // Lancet. 2012. Vol. 380 (9836). P. 29–36.Stein E. A., Gipe D., Bergeron J. et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial // Lancet. 2012. Vol. 380 (9836). P. 29–36.Dias C. S., Shaywitz A. J., Wasserman S. M. et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, doubleblind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins // J. Am. Coll. Cardiol. 2012. Nov. 6. Vol. 60, N 19. P. 1888–1898.Dias C. S., Shaywitz A. J., Wasserman S. M. et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, doubleblind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins // J. Am. Coll. Cardiol. 2012. Nov. 6. Vol. 60, N 19. P. 1888–1898.Sullivan D., Olsson A. G., Scott R. et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial // JAMA. 2012. Dec. 19. Vol. 308, N 23. P. 2497–2506.Sullivan D., Olsson A. G., Scott R. et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial // JAMA. 2012. Dec. 19. Vol. 308, N 23. P. 2497–2506.Raal F., Scott R., Somaratne R. et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin / kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial // Circulation. 2012. Nov. 13. Vol. 126, N 20. P. 2408–2417.Raal F., Scott R., Somaratne R. et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin / kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial // Circulation. 2012. Nov. 13. Vol. 126, N 20. P. 2408–2417.Koren M. J., Scott R., Kim J. B. et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as mono therapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study // Lancet. 2012. Dec. 8. Vol. 380. (9858). P. 1995–2006.Koren M. J., Scott R., Kim J. B. et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as mono therapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study // Lancet. 2012. Dec. 8. Vol. 380. (9858). P. 1995–2006.Giugliano R. P., Desai N. R., Kohli P. et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin / kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study // Ibid. P. 2007–2017.Giugliano R. P., Desai N. R., Kohli P. et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin / kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study // Ibid. P. 2007–2017.Stein E. A., Honarpour N., Wasserman S. M. et al. Effect of the PCSK9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia // Circulation. 2013. Sep. 6.Stein E. A., Honarpour N., Wasserman S. M. et al. Effect of the PCSK9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia // Circulation. 2013. Sep. 6.Stein E. A., Swergold G. D. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics // Curr. Atheroscler. Rep. 2013. Mar. Vol. 15, N 3. P. 310.Stein E. A., Swergold G. D. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics // Curr. Atheroscler. Rep. 2013. Mar. Vol. 15, N 3. P. 310.Davidson M. H. Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction // J. Clin. Lipidol. 2013. May-Jun. Vol. 7. (3 Suppl). P. S11–S15.Davidson M. H. Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction // J. Clin. Lipidol. 2013. May-Jun. Vol. 7. (3 Suppl). P. S11–S15.Lee P., Hegele R. A. Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia // Expert. Opin. Investig. Drugs. 2013. Jul. 26.Lee P., Hegele R. A. Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia // Expert. Opin. Investig. Drugs. 2013. Jul. 26.

The authors declare that there are no conflicts of interest present.